Teva reclaims its spot as top generic drug maker
Israel-based Teva Pharmaceutical Industries entered an agreement to buy U.S.-based Ivax Corp. today for $7.4 billion in cash and stock ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.